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Background: To determine the efficacy of high-dose antioxidants in the acute stage of central serous
chorioretinopathy (CSC).
Methods: This was a randomized placebo-controlled study. The patients with acute CSC (onset within 6 weeks)
were randomized to receive either high-dose antioxidant tablets (study group A) or placebo tablets (control group
B) for 3 months or until the complete resolution of subretinal fluid. After 3 months, additional treatment with laser
or photodynamic therapy (PDT) was considered if any fluorescein leakage persisted. The outcomes measured were
the changes in visual acuity (VA) and central macular thickness (CMT), the number of patients with subretinal fluid
at each follow-up time, the number of patients with fluorescein leakage at the end of the 3rd month and patients
who received additional treatments.
Results: Fifty-one of 58 patients (88%) completed the follow-up criteria. The baseline demographic data were
comparable in both groups. At the end of the 3rd month, the VA and CMT showed no statistical difference
between the groups but the patients in group A has less fluorescein leakage and additional treatments than in
group B (p = 0.027 and 0.03).
Conclusion: The high-dose antioxidants for acute CSC did not show any benefits in VA and CMT. However, the
drugs might decrease the chance for fluorescein leakage and additional treatments at the end of the 3rd month.
Keywords: Antioxidants, Central serous chorioretinopathyBackground
Central serous chorioretinopathy (CSC) is a serous neuro-
sensory detachment that usually involves the macular
area. It is common in patients between the ages of 30–
50 years and affects males more often than females with a
ratio of 2:1 [1,2]. The common risk factors are psycho-
logical stress, type A personality, systemic steroid use,
hypertension and pregnancy [3-5]. The treatment is usu-
ally observation especially in the first three months. Laser
or photodynamic therapy (PDT) should be considered
when the condition does not improve after that time.
Nevertheless, the pathogenesis of CSC is still not well
understood but the study from indocyanine green (ICG)
angiography showed choroidal vascular hyperpermeability* Correspondence: mratanasukon@yahoo.com
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distribution, and reproduction in any mediumand abnormal leakage [6-8]. The causes of this abnormal-
ity are supposed to come from nitric oxide, prostaglandins
or even free oxidative radicals [3,6-8]. From this hypoth-
esis, the oxidative process might be involved in the patho-
genesis of the disease especially in the early stage. This
study is to determine the effect of antioxidant drugs in the
acute stage of CSC and to determine whether they can im-
prove the outcome of the disease.Methods
The study is a prospective, randomized, placebo-
controlled study for high-dose oral antioxidants for
patients who presented with acute CSC between Decem-
ber 2004 and December 2008 at the Retina Unit, Prince
of Songkla University, Thailand. The research was
approved by the Ethics Committee, Faculty of Medicine,
Prince of Songkla University in December 2004 (EC 47/entral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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the consent forms. The patients were randomly assigned
to high-dose antioxidant or placebo drugs. The
randomization was computer generated with a 1:1 ratio,
block lengths of 4 and random numbers were coded to
all bottles. Moreover, the codes were in envelops until
the end of the study. The inclusion criteria were patients
with acute CSC (within 6 weeks of onset), aged between
30–50 years, new or recurrent attack (symptom-free
6 months or longer), a fluorescein angiography (FA)
confirmed diagnosis with inkblot (Figure 1) or smoke-
stack leakage, an optical coherence tomography (OCT)
by Stratus OCT™ (Carl Zeiss Meditec, Inc., Dublin, CA)
showing definite subretinal fluid and the patients’ ability
for proper follow-up. The exclusion criteria were chronic
CSC (longer than 6 weeks), multiple attacks (more than
2 times), large pigment epithelial detachment (more than
1 disc diameter), multiple pigment epithelial detachment
or diffuse retinal pigment epitheliopathy, younger or
older ages, a follow-up time less than 3 months, a com-
plicated CSC such as secondary choroidal neovasculari-
zation detected from FA, pregnancy, steroid use and
patients with contraindication for high-dose antioxidants
therapy such as heavy smokers, those with lung cancer,
thyrotoxicosis, renal stones and anemia (hematocrit less
than 30%).
The study group (group A) received high-dose antioxi-
dant tablets (IcapsTM, Alcon Laboratories) that con-
tained vitamin A (6600 IU), vitamin C (400 mg), vitamin
E (150 IU), riboflavin (10 mg), zinc (60 mg), copper
(4 mg), selenium (40 mg), manganese (4 mg) and lutein/
zeaxanthin (4000 micrograms). The drug was taken im-
mediately after diagnosis, 1 tablet two times a day after
meals for 3 months or until the complete resolution of
subretinal fluid as assessed by OCT.Figure 1 The patient with central serous chorioretinopathy
showed typical inkblot leakage in the early phase (left) and late
phase (right) from fluorescein angiography.The control group (group B) received placebo tablets
that were specially made for the study and were identical
to the study tablets in their size, color and identification
name and were taken in similar ways as the study drugs.
Both drugs were also in identical opaque bottles and
prepared by one non-clinician research assistant.
The study was an intention-to-treat analysis and
there was no cross-over of patients between the
groups after the study. The corresponding author (M.R.)
generated the allocation sequence, enrolled the patients
and assigned patients to any additional treatments when
needed.
The patients were scheduled for follow-up every
month. The visual acuity (VA), using the logarithm of
minimum angle of resolution (logMAR), OCT using
central macular thickness (CMT), FA and any complica-
tions were assessed during each visit. The study drug or
placebo drug was discontinued in a patient when OCT
demonstrated complete resolution of subretinal fluid or
at the end of the 3rd month after finishing 3 bottles of
the drug. After 3 months, additional treatments such as
laser photocoagulation for extrafoveal leakage or PDT
for juxtafoveal or subfoveal leakage were considered for
any persistent FA leakage (Figure 2).
The primary outcomes were the changes in VA and
CMT recorded by OCT during every visit. The second-
ary outcomes were the number of patients with subret-
inal fluid at each follow-up time, the number of patients
who showed FA leakage at the end of the 3rd month and
patients who received additional treatments in each
group.
The sample size was calculated with α= 0.05 (two-
sided), β= 0.2 and determined to be approximately 24
patients in each group. Assuming an expected dropout
rate of 20%, 29 patients in each group were needed. An
independent t-test was used for parametric data. The
chi-square and Mann Whitney U-test were used for
non-parametric data. A p-value less than 0.05 was con-
sidered significant.
Results
A total of 58 eyes in 58 patients were included in the
study and were randomized equally with 29 eyes in each
group. Seven eyes (12%) were lost to follow-up or did
not have enough data for analysis at the 3rd month (3
eyes in the study group and 4 eyes in the control group).
A total of 51 eyes (88%) were included in the final ana-
lysis (Figure 2).
The mean age and duration of CSC before enrollment
of both groups were 40.4 years and 15.4 days. Although
the study group showed a lower mean onset duration
time than the control group (13.2 vs 17.5 days), the
p-value demonstrated no statistical difference (p = 0.09).
The mean baseline VA, CMT as determined by OCT and
Figure 2 The trial profile, CSC= central serous chorioretinopathy, PDT=photodynamic therapy, Study group (group A): the group
received antioxidant tablets, Control group (group B): the group received placebo tablets.
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and 8.6 months, respectively. Most of OCT findings in
both groups showed subretinal fluid and/or intraretinal
edema but very few cases had cystoid macular edema.
The baseline fluorescein leakage pattern of most cases
(52 eyes, 90%) was inkblot leakage and only 6 eyes (10%,
3 in each group) demonstrated a smokestack pattern.
The baseline demographic data are summarized in
Table 1 and show no statistical significance between any
of the parameters for both groups.
At the end of the 3rd month, all patients showed no
significant side effects. The VA and CMT in both groupsTable 1 Demographic Data of the Study and Control Groups
Study group
(group A)
Age (years ± SD) 41.28 ± 5.07
Sex (M/F) 23/6
Duration before diagnosis (days ± SD) 13.24 ± 9.65
Initial VA (logMAR± SD) 0.23 ± 0.27
Initial CMT (microns ± SD) 524.28 ± 175.95
FA findings at baseline
- inkblot leakage 26
- smokestack leakage 3
Study group (group A): the group received antioxidant tablets.
Control group (group B): the group received placebo tablets.
SD= standard deviation.
M=male, F = female, VA= visual acuity.
logMAR= logarithm of minimum angle of resolution.
CMT= central macular thickness.
FA = fluorescein angiography.also showed no statistical differences (p = 1.0 and 0.25,
Figure 3, 4). Regarding the secondary outcomes, the
number of eyes with subretinal fluid at the 3rd month
was higher in the control group than the study group
(Table 2). Moreover, the number of eyes that demon-
strated fluorescein leakage at the end of the 3rd month
was also higher in the control group (10 eyes) than in
the study group (3 eyes) (odds ratio, 0.19; 95% CI, 0.046-
0.83; p = 0.027) (Table 2). These patients were the same
group of the patients with subretinal fluid at the 3rd
month. These results imply that the study drug might
affect the leakage activity more than the fluid (bothControl group
(group B)
p-value
39.48 ± 6.95 0.27
25/4 0.49
17.55 ± 9.66 0.09
0.27 ± 0.20 0.59
508.69 ± 135.31 0.70
26 -
3 1.00
Figure 3 The mean visual acuity (VA) at each follow-up time between the study and control group. Study group (group A): the group
received antioxidant tablets, Control group (group B): the group received placebo tablets, VA = visual acuity, logMAR = logarithm of
minimum angle of resolution.
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ment epithelium. With regards to the recurrent rate, 3
patients developed a recurrent attack: 1 eye in the study
group and 2 eyes in the control group (p = 0.29). Two of
them (one in each group) had received additional treat-
ments at the end of the 5th and 8th month, whereas an-
other one had spontaneous resolution of subretinal fluid
without any treatment.Figure 4 The mean central macular thickness (CMT) at each follow-up
A): the group received antioxidant tablets, Control group (group B): t
thickness.Because of the difference in leakage activities after
3 months of randomization, 4 patients in the study group
and 11 patients in the control group were considered for
additional laser treatment or PDT (including 2 recurrent
cases). The p-value also demonstrated significance (odds
ratio, 0.23; 95% CI, 0.061-0.872; p = 0.03) in terms of these
additional treatments (Table 2). Thereafter, although the
study showed no significance between the final VA andtime between the study and control group. Study group (group
he group received placebo tablets, CMT = central macular
Table 2 The Study Results
Study group (group A) Control group (group B) p-value Odds ratio 95% CI
Number of patients -at 1st month 26 29 0.2 - -
-at 3rd month 26 25 1.00
-at 6th month 16 14 0.79
-at 12th month 7 7 1.00
VA (logMAR± SD) -at 3rd m. 0.09 ± 0.20 0.09 ± 0.09 0.99 - -
-at 6th m. 0.05 ± 0.06 0.04 ± 0.06 0.60
-at 12th m. 0.04 ± 0.05 0.03 ± 0.05 0.91
CMT (microns ± SD) -at 3rd m. 220.65 ± 94.37 243.84 ± 76.13 0.34 - -
-at 6th m. 193.20 ± 46.38 183.22 ± 22.59 0.41
-at 12th m. 180.00 ± 15.05 186.22 ± 20.62 0.42
Patients with subretinal fluid (number of patients)
-at 1st month 22 23 0.73 - -
-at 2nd month 13 14 0.78 - -
-at 3rd month 3 10 0.027 0.196 0.046-0.830
Follow-up time (m± SD) 9.04 ± 6.69 8.14 ± 8.69 0.67 - -
FA leakage at 3rd m. (patients) 3 10 0.027 0.196 0.046 - 0.830
- inkblot leakage 2 9 - - -
- smokestack leakage 1 1 0.94 - -
Laser or PDT (number of patients) 4 11 0.03 0.231 0.061 - 0.872
Recurrence (number of patients) 1 2 0.29 - -
Study group (group A): the group received antioxidant tablets.
Control group (group B): the group received placebo tablets.
CI = confidence interval.
VA = visual acuity, logMAR= logarithm of minimum angle of resolution.
SD= standard deviation.
m=month, CMT= central macular thickness.
FA = fluorescein angiography, PDT = photodynamic therapy.
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patients who received high-dose antioxidants in the acute
phase of the disease had less of a chance of having subret-
inal fluid and being treated by laser or PDT at the end of
the 3rd month.
Discussion
Central serous chorioretinopathy (CSC) is a disease that
affects young patients and sometimes results in chronic
maculopathy that might permanently affect visual acuity.
The disease usually resolves itself within three months
after the onset and treatment using laser or PDT should
be considered only after that time [1,9,10]. Before the
end of the 3rd month, there are many modalities studied
to treat CSC such as multivitamins and acetazolamide
tablets. Pikkle et al. demonstrated the effect of acetazola-
mide in treating CSC and showed some benefit when
compared with placebo [11]. Moreover, there is some
evidence that the oxidative process might be the cause
of RPE/choroidal abnormality and subretinal fluid in
CSC [3,6-8], so the main objective in this study is to
postulate a new drug modality in treating acute onsetCSC and to determine whether the drug can improve
the visual outcomes and/or decrease the chance of laser
treatment or PDT at the end of the 3rd month.
Various mechanisms or processes have been proposed
for the pathogenesis of CSC. A study from indocyanine
green (ICG) angiography demonstrated that choroidal ab-
normalities such as dilatation and leakage were supposed
to be the primary affected areas. These abnormalities
could induce secondary RPE changes and result in the ac-
cumulation of intraretinal and subretinal fluid [6]. Laser
treatment, however, was aimed to reduce subretinal fluid
by direct photocoagulation to decrease any fluorescein
leakage but did not affect directly the entire choroidal ves-
sel abnormalities. PDT is the first to treat the choroidal
leakage directly and gave good results [9,10]. Nevertheless,
the exact mechanisms of these choroidal abnormalities
are still unknown. The previous studies proposed that
choroidal ischemia and/or an abnormality in the autore-
gulation of choroidal blood flow from nitric oxide, prosta-
glandins and free radicals from the oxidative process
might be involved in the pathogenesis [3,6-8]. Therefore,
medications such as the available antioxidant tablets
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pecially in the early stage of the disease.
This study was conducted only for the acute stage of
CSC (less than 6 weeks of onset) with the mean time of
duration of about 13.2 and 17.5 days in the study group
and control group (p = 0.09). The study also excluded
cases with complicated CSC such as diffuse pigment
epitheliopathy or large pigment epithelial detachment.
This means that the patients in both groups should have
similar patterns of the disease in terms of pathogenesis,
disease progression and even prognosis. At every follow-
up, the VA and CMT determined by OCT of both
groups showed no statistical significance. This might
allow one to conclude that the antioxidant drugs do not
have any beneficial effects on acute CSC. However, this
conclusion should be accepted with caution because at
the end of the 3rd month many patients especially in the
control group received additional treatments due to per-
sistent fluorescein leakage. Thereafter, the final visual
outcomes and CMT were modified by treatments such
as laser or PDT at that time and might affect primary
outcomes. Moreover, the CMT is the combined meas-
urement of both intraretinal and subretinal fluid of the
central macula so it might not reflect the CSC activity
after the treatments, such as the rate of subretinal fluid
absorption, especially at the end of the 3rd month. With
this in mind, we also conducted the study noting the
number of patients with subretinal fluid at each follow-
up time, fluorescein leakage patterns and the need for
additional treatments for the secondary outcomes.
The fluorescein patterns from the study demonstrated
interesting results. At the end of the 3rd month, 3
patients in the study group and 10 patients in the con-
trol group still had fluorescein leakage (p = 0.027,
Table 2). These results followed the difference in the
number of patients with subretinal fluid at the same
follow-up time and led to more chances of patients in
the placebo group having additional treatments such as
laser or PDT. These small group of slower-resolution
might be caused by various reasons such as the differ-
ence in patients’ personality, stress, smoking, or even
oxidative stress. As mentioned above, the previous stud-
ies [3,6-8] proposed the oxidative process to be involved
in the condition and it might cause some patients to
have slower resolution than expected. However, the oxi-
dative process might show different effect in various
structures of the retina. If the choroid were attacked by
oxidative radicals, this could have secondary effects on
the RPE, followed by the accumulation of both intraret-
inal and subretinal fluid. The oxidative process might
have a greater effect in choroidal abnormalities than the
RPE pumping activity. This leads patients in the control
group to have a higher chance of having subretinal fluid
and persistent fluorescein leakage than in the studygroup. It was also confirmed from the study that the
final CMT by OCT that measured both intraretinal and
subretinal fluid demonstrated a similar pattern of slow
resolution in both groups and showed no statistical sig-
nificance between the groups in any of the follow-up
periods. This means that the antioxidant drugs
decreased the choroidal leakage (which clinically pre-
sented as subretinal fluid and fluorescein leakage) and
the resolution of intraretinal fluid that was partly
affected by the RPE pumping activity was modified less
by the drugs and led to the same CMT study results be-
tween the groups. Therefore, antioxidant drugs might
have a more beneficial effect on choroidal leakage than
RPE pumping activity and give a patient less of a chance
to have persistent fluorescein leakage and additional
treatments. However, as mentioned, this study did not
take into account the complicated or chronic CSC so
the role of antioxidant drugs in such conditions is
unknown.
There are some limitations in this study. Some
patients were lost from the schedule and the follow-up
time was short. Although the recurrent cases were not
significant between the groups (p = 0.29), the recurrent
rate in the study was still inconclusive because the sam-
ple size of recurrence of only 3 eyes was too small for
analysis. A long term follow-up will be organized in the
near future to answer the questions of any difference in
recurrent rates and any long-term side effects that might
have occurred by using the drugs. Another limitation is
the use of time domain OCT instead of spectral domain
OCT. The previous generation of OCT machines cannot
evaluate well the quantification of the subretinal fluid
pockets. A future trial using spectral domain OCT
would be beneficial as it would better allow evaluation
of the fluid via editing segmentation. The difference in
the fluorescein leakage patterns is also a limitation in
this study. Because most of the cases were inkblot leak-
age (90%) and only 10% showed smokestack pattern we
could not do a subgroup analysis of the two leakage
patterns.
Conclusions
Although the antioxidant drug treatment does not have
a benefit in visual acuity and central macular thickness
in acute CSC, there might be less of a chance for persist-
ent fluorescein leakage and the need for additional treat-
ments such as laser or PDT. A randomized controlled
study with a longer follow-up and quantitative analysis
of the subretinal fluid is warranted to investigate antioxi-
dants as a possible treatment modality.
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